uniQure N.V. - Ordinary Shares — キャッシュフロー (NASDAQ:QURE)

Financials

営業活動によるキャッシュフロー -134.83 M287.96 M-145.06 M-145.93 M-182.73 M-177.96 M -172.11 M 投資活動によるキャッシュフロー -9.48 M-67.39 M-182.73 M-205.69 M162.97 M-321.62 M -243.16 M 財務活動によるキャッシュフロー 7.44 M94.86 M1.45 M362.72 M-59.49 M415.4 M 335.28 M フリーキャッシュフロー -134.83 M287.96 M-145.06 M-145.93 M-182.73 M-178.4 M -172.56 M

uniQure N.V. - Ordinary Shares

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

QURE

Financials

uniQure N.V. - Ordinary Shares

ニュース

Biotech Investors Are Tuning Out the MAHA Chaos

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks.com

Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?

PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors

A Unique Situation For UniQure (QURE)

FDAの指導部交代を受けてMizuhoがuniQure株の格付けを引き上げ

Mizuho upgrades uniQure stock rating on FDA leadership change

Avago, Lumentum among market cap stock movers on Monday

Chardan、FDA指導部交代を受けてuniQure株の目標株価を引き上げ